Navigation Links
Novartis and collaborators discover novel antimalarial drug candidate
Date:9/2/2010

Singapore, September 3, 2010 Novartis announced today that scientists at the Novartis Institute for Tropical Diseases (NITD), in collaboration with researchers from the Genomics Institute of the Novartis Research Foundation (GNF), the Swiss Tropical and Public Health Institute and The Scripps Research Institute have discovered a novel compound that shows promise as a next generation treatment for drug resistant malaria. Major support for the project was provided by the Wellcome Trust, the Medicines for Malaria Venture (MMV), A*STAR, Singapore and the U.S. government.

Published this week in Science the findings demonstrate that the antimalarial candidate, spiroindolone NITD609, is effective against both strains of the malaria parasite, Plasmodium (P.) falciparum and P. vivax. Through a novel mechanism NITD609 rapidly clears plasmodium in a malaria mouse model and shows pharmacological properties compatible with a once-daily dosing regimen. Copies of the embargoed Science paper are available at scipak@aaas.org.

According to the World Health Organization (WHO), in 2008 there were approximately 247 million cases of malaria, causing nearly one million deaths, mostly among young children in Africa. Although malaria is preventable and curable, it is estimated that in Africa, a child dies every 45 seconds from the disease.1

"Malaria remains a scourge," said Mark Fishman, president, Novartis Institutes for BioMedical Research. "The parasite has demonstrated a frustrating ability to outwit new medicines, from quinine to today's unsettling increased tolerance to artemisinin derivatives. We are delighted that our scientists could provide this potential new malaria therapy, based on an unprecedented chemical structure and directed to a novel target."

Further regulatory pharmacological and safety evaluation is currently ongoing and, provided the outcome of these studies is
'/>"/>

Contact: Mariellen Gallagher
mariellen.gallagher@novartis.com
001-617-871-7665
Novartis Institutes for BioMedical Research
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. Novartis awards 2010 Prizes for Immunology in recognition of outstanding contributions to immunology in medical research
2. Clemson and collaborators receive $1.1 million to improve durability of concrete infrastructure
3. K-State researcher, collaborators study virulence of pandemic H1N1 virus
4. Formula discovered for longer plant life
5. Chemical equator discovery will aid pollution mapping
6. Researchers discover that growing up too fast may mean dying young in honey bees
7. Scientists discover why a mothers high-fat diet contributes to obesity in her children
8. Sirtris review of sirtuin therapeutics for diseases of aging in Nature Reviews Drug Discovery
9. Groundbreaking discovery may lead to stronger antibiotics
10. Discovery of natural compounds that could slow blood vessel growth
11. Earliest animal footprints ever found -- discovered in Nevada
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/16/2014)... 2014) – Post-menopausal women experienced improvements in vaginal ... or genital bleeding, after 12 weeks of daily ... soy germ-based nutritional supplement previously shown to help ... peer-reviewed pilot study reported in a poster at ... meeting. , "These data documented improved vaginal ...
(Date:10/15/2014)... non-traditional biophysics textbook and it describes how life functions ... discovery into biological systems and provides an understanding of ... about how our genes make proteins that control the ... in an organism. It quantifies the principles of life ... found on both large and small scales. The book ...
(Date:10/15/2014)... SHELTON, Conn. , Oct. 15, 2014 NXT-ID, Inc. ... a biometric authentication company focused on the growing mobile commerce market ... NASDAQ MarketSite in Times Square on Monday October 13 th . ... with CTO David Tunnel and angel investor Mr. ... Gino Pereira , CEO of NXT-ID thanked his investors and employees ...
Breaking Biology News(10 mins):S-equol supplements associated with improved measures of reproductive health in postmenopausal women 2New book about life as seen from physics 2Photo Release: NXT-ID Inc. Rings Opening Bell of the NASDAQ Stock Market October 13th 2Photo Release: NXT-ID Inc. Rings Opening Bell of the NASDAQ Stock Market October 13th 3
... Digging into Data Challenge was announced by four ... (JISC) from the United Kingdom, the National Endowment ... Foundation (NSF) from the United States, and the ... Canada. The Digging into Data ...
... a greater rate than other places in the Northern ... future. As a result, glacier and ice-sheet melting, ... be expected to continue. A new comprehensive scientific ... time the pervasive nature of Arctic climate amplification. ...
... 12, 2009 The 2009 winners of the National ... M.D. and Lee Goodglick, Ph.D. The $100,000 grants will ... the role of estrogen in lung cancer tumors, respectively. ... lung cancer at Memorial Sloan-Kettering Cancer Center in New ...
Cached Biology News:Leading research agencies announce new international competition: "The digging into data challenge" 2Arctic heats up more than other places 2National Lung Cancer Partnership and LUNGevity Foundation announce 2009 grant recipients 2
(Date:10/22/2014)... , Oct. 22, 2014  Actavis plc (NYSE: ... and Rhythm, a biopharmaceutical company, today announced that Actavis ... wholly owned subsidiary, Rhythm Health, Inc., which is developing ... of diabetic gastroparesis and other GI functional disorders. ... trial of relamorelin for the treatment of diabetic gastroparesis ...
(Date:10/22/2014)... Involution Studios , a healthcare software design ... Understanding Ebola . The goal of the ... follow informative tool for anyone wanting to know more ... , "As the news has spread in all directions ... not only a healthcare crisis with global impact, but ...
(Date:10/22/2014)... 2014 Physicians Choice Laboratory Services ... menu, which enables healthcare providers to individualize therapeutic ... evidence-based results, healthcare providers are better able to ... while minimizing risks for adverse drug reactions and ... the FDA [1] more than 2.2 million adverse ...
(Date:10/22/2014)... , Oct. 22, 2014 Nuvilex, Inc. ... approximately 400 million people worldwide are living with diabetes, ... people by 2030.  The global market for diabetes treatments ... approximately 330,000 people worldwide died from pancreatic cancer.  Pancreatic ... due to cancer in the United States ...
Breaking Biology Technology:Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 2Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 3Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 4Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 5Involution Studios' Ebola Infographic Provides Key Disease Information and Statistics at a Glance 2PCLS Announces Expansion of Cardiovascular Pharmacogenetic Testing Menu 2PCLS Announces Expansion of Cardiovascular Pharmacogenetic Testing Menu 3Nuvilex Brief Analyst Report: Thinking Outside the Box by BrokerBank Securities, Inc. 2
... marine scientists from across the world have issued a ... offsets from ocean iron fertilisation. , Published on Friday ... US, Japan, Hawaii, New Zealand, The Netherlands, India, Germany ... Andrew Watson of the University of East Anglia and ...
... 10 BioCryst,Pharmaceuticals, Inc. (Nasdaq: BCRX ) ... as a consultant and interim Chief Medical Officer. ... in global pharmaceutical,development to his position at BioCryst., ... are very pleased to have Tom join BioCryst ...
... News, Va. Also ... Recognized, CHICAGO, ... achievements in its,community, Harborview Medical Center of Seattle is the recipient of ... esteemed,honors of excellence in community service in healthcare. As one of two,primary ...
Cached Biology Technology:BioCryst Strengthens Its Expertise in Clinical Development By Adding Thomas J. Simon, M.D. as Interim Chief Medical Officer To Meet Growing Product Development and Commercial Opportunities 2BioCryst Strengthens Its Expertise in Clinical Development By Adding Thomas J. Simon, M.D. as Interim Chief Medical Officer To Meet Growing Product Development and Commercial Opportunities 3BioCryst Strengthens Its Expertise in Clinical Development By Adding Thomas J. Simon, M.D. as Interim Chief Medical Officer To Meet Growing Product Development and Commercial Opportunities 4Harborview Medical Center in Seattle Receives Prestigious $100,000 Foster G. McGaw Prize for Excellence in Community Service 2Harborview Medical Center in Seattle Receives Prestigious $100,000 Foster G. McGaw Prize for Excellence in Community Service 3Harborview Medical Center in Seattle Receives Prestigious $100,000 Foster G. McGaw Prize for Excellence in Community Service 4Harborview Medical Center in Seattle Receives Prestigious $100,000 Foster G. McGaw Prize for Excellence in Community Service 5Harborview Medical Center in Seattle Receives Prestigious $100,000 Foster G. McGaw Prize for Excellence in Community Service 6
Umbilical cord blood neutrophils, For immunohistochemistry (IHC)...
...
Adjustable tilt angle 0 to 20 Adjustable speed of 3-25 RPM Load capacity: 2.7 kg (6 lbs.) Ambient temperature range 4C to 65C Low voltage power is supplied by wall mount transformer...
... Clean spin filters allow for the rapid isolation ... your DNA gel slice in the spin filter, ... your DNA is recovered. There is no need ... buffers. Spin filters can also be used for ...
Biology Products: